See more news releases in: Publishing & Information Services, Health Care & Hospitals, Pharmaceuticals, Surveys, Polls and Research
Reportlinker Adds Merck KGaA: PharmaVitae Profile
NEW YORK, April 6 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Merck KGaA: PharmaVitae Profile
http://www.reportlinker.com/p0186215/Merck-KGaA-PharmaVitae-Profile.html
Introduction
This analysis examines the historical and forecast performance for Merck KGaA in the prescription pharma sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
Reasons to Purchase
*Benchmark Merck KGaA's performance against key rivals in the prescription pharmaceutical sector
*Learn how the continued strong performance of Erbitux will drive the company's prescription pharma business in the period to 2015
*Evaluate the company's more focused business strategy and see how its extensive restructuring has affected its operating cost and profit margins
CHAPTER 1 ABOUT THIS PROFILE 2
Executive summary 2
Quarterly news update 2
Company introduction 2
Company sales 2
Company financials 2
Key products and competitors 3
Data sourcing 3
Sales data 3
Analyst consensus 3
CHAPTER 2 EXECUTIVE SUMMARY 4
Key findings 4
Prescription pharmaceutical sales performance, 2001-13 5
Financial performance, 2001-13 6
Merck KGaA: PharmaVitae forecasts at a glance 7
Strategic insight 8
Erbitux and Serono acquisition rejuvenate branded Rx pharma business... 8
...and diversify Merck KGaA's portfolio to improve long-term prospects 9
From pure-play small molecule company to biopharmaceutical 10
Expansion into CNS and oncology 11
Breaking into the US 12
A 'younger' product portfolio 13
Re-structuring bolsters financial performance 14
SWOT analysis 17
Strengths 17
Growth prospects of Erbitux 17
Broad portfolio supported by pipeline 18
Continued sales growth from off-patent products 18
Weaknesses 18
Over reliance on Erbitux to drive growth 18
Opportunities 19
Expansion of oncology portfolio through continued growth of Erbitux and development of pipeline candidates 19
Continued improvement of operating profit margin 19
Use high revenues to pursue licensing deals to further bolster portfolio 20
Pursue M&A opportunities to build consumer health and life sciences businesses 20
Threats 20
Increasing competition from biosimilars is affecting the growth prospects of Merck KGaA's therapeutic protein franchise 20
CHAPTER 3 QUARTERLY NEWS UPDATE 25
Product developments 25
Deals and alliances 26
Product deals 26
Technology deals 31
M&A activity 33
Company announcements 34
Future product milestones 38
CHAPTER 4 COMPANY INTRODUCTION 39
Key findings 39
Background 40
Key corporate developments 40
M&A history 41
Merck-Serono Biopharmaceuticals 41
Divestment of generics business 41
Streamlined focus 42
Current corporate structure 42
Pharmaceuticals 43
Branded prescription pharmaceuticals 43
Consumer health 43
Chemicals 44
Performance & life science chemicals 44
Liquid crystals 44
Pharmaceuticals business unit structure 45
CHAPTER 5 COMPANY SALES 46
Key findings 46
Prescription pharmaceutical sales and growth rate analysis, 2001-13 48
Product analysis 50
Product analysis, 2001-07 50
Product analysis, 2007-13 53
Therapy area analysis 56
Therapy area analysis, 2001-07 57
Therapy area analysis, 2007-13 59
Therapy area focus, 2001-13 61
Geographic analysis 63
Geographic analysis, 2001-07 64
Geographic analysis, 2007-13 66
Geographic focus, 2001-13 68
Launch/core/expiry analysis 69
Explanation of launch/core/expiry analysis 69
Launch analysis, 2007-13 70
Core analysis, 2007-13 71
Expiry analysis, 2007-13 72
Launch/core/expiry configuration, 2007-13 73
Molecule type analysis 75
Molecule type analysis, 2001-07 76
Molecule type analysis, 2007-13 77
Externalization analysis 79
Externalization analysis, 2001-07 80
Externalization analysis, 2007-13 81
CHAPTER 6 COMPANY FINANCIALS 83
Key findings 83
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2001-07 84
Financial statements, 2001-07 86
Profit and loss account, 2001-07 86
Balance sheet, 2001-07 88
Operating costs and profit analysis 90
Operating costs and profit analysis, 2001-07 91
Operating cost ratio and profit margin analysis, 2001-07 92
Operating cost ratio and profit margin analysis, 2007-13 93
Operating costs and profit analysis, 2007-13 95
Return on capital employed analysis 97
Capital employed analysis, 2001-07 98
Return on capital employed (RoCE) analysis, 2001-07 100
Market capitalization analysis 103
Market capitalization analysis, 2001-07 103
Total shareholder returns analysis, 2001-07 104
CHAPTER 7 KEY PRODUCTS AND COMPETITORS 106
Key findings 106
Overview 107
CNS 108
Rebif 108
Overview 108
Sales forecast 109
Mylinax 113
Overview 113
Sales forecast 114
safinamide 117
Overview 117
Sales forecast 118
Oncology 121
Erbitux 121
Overview 121
Sales forecast 122
Cardiovascular 124
Concor & Concor-Plus 124
Overview 124
Sales forecast 125
Kuvan 126
Overview 126
Sales forecast 127
Urology & gender-specific health 128
Gonal-F 128
Overview 128
Sales forecast 129
Endocrine, metabolic and genetic disorders 132
Glucophage & Glucovance 132
Overview 132
Sales forecast 133
CHAPTER 8 APPENDIX 134
R&D pipeline 134
References 135
Papers 135
Company releases 135
Datamonitor reports 135
News articles 136
Abbreviations 136
Exchange rates 137
List of Tables
Table 1: Merck KGaA - PharmaVitae forecasts at a glance 7
Table 2: Merck KGaA key product developments, Q1 2008-Q1 2009 25
Table 3: Merck KGaA product deals and alliances, Q1 2008-Q1 2009 26
Table 4: Merck KGaA technology deals and alliances, Q1 2008-Q1 2009 31
Table 5: Merck KGaA M&A activity, Q1 2008-Q1 2009 33
Table 6: Merck KGaA company announcements, Q1 2008-Q1 2009 34
Table 7: Merck KGaA future product milestones, 2009-10 38
Table 8: Merck KGaA, product portfolio overview ($m), 2001-07 50
Table 9: Merck KGaA, product portfolio overview ($m), 2007-13 53
Table 10: Merck KGaA, therapy portfolio overview ($m), 2001-07 57
Table 11: Merck KGaA, therapy portfolio overview ($m), 2007-13 59
Table 12: Merck KGaA, portfolio overview by geographic region ($m), 2001-07 64
Table 13: Merck KGaA portfolio overview by geographic region ($m), 2007-13 66
Table 14: Merck KGaA launch portfolio overview ($m), 2007-13 70
Table 15: Merck KGaA core portfolio overview ($m), 2007-13 71
Table 16: Merck KGaA expiry portfolio overview ($m), 2007-13 72
Table 17: Merck KGaA portfolio overview by molecule type ($m), 2001-07 76
Table 18: Merck KGaA product portfolio overview by molecule type ($m), 2007-13 77
Table 19: Merck KGaA product portfolio overview by source ($m), 2001-07 80
Table 20: Merck KGaA product portfolio overview by source ($m), 2007-13 81
Table 21: Total Merck KGaA sales by business unit ($m), 2001-07 84
Table 22: Merck KGaA profit and loss account ($m), 2001-07 86
Table 23: Merck KGaA balance sheet ($m), 2001-07 88
Table 24: Merck KGaA operating revenue/cost analysis ($m), 2001-07 91
Table 25: Merck KGaA operating cost ratio analysis (% of total revenues), 2001-07 92
Table 26: Merck KGaA operating cost ratio analysis (% of total revenues), 2007-13 93
Table 27: Merck KGaA operating revenue/cost analysis ($m), 2007-13 95
Table 28: Merck KGaA capital employed ($m), 2001-07 98
Table 29: Merck KGaA EBIT return on capital employed ($m), 2001-07 100
Table 30: Merck KGaA EBIT pre-tax return/capital employed driver analysis (%), 2001-07 101
Table 31: Merck KGaA market capitalization ($ billion), 2001-07 103
Table 32: Merck KGaA total shareholder returns (annual %), 2001-07 104
Table 33: Key products overview 107
Table 34: Rebif: overview 108
Table 35: Rebif: sales forecast ($m), 2007-13 109
Table 36: Mylinax: overview 113
Table 37: Mylinax: sales forecast ($m), 2007-13 114
Table 38: safinamide: overview 117
Table 39: safinamide: sales forecast ($m), 2007-13 118
Table 40: Erbitux: overview 121
Table 41: Erbitux: sales forecast ($m), 2007-13 122
Table 42: Concor & Concor-Plus: overview 124
Table 43: Concor & Concor-Plus: sales forecast ($m), 2007-13 125
Table 44: Kuvan: overview 126
Table 45: Kuvan: sales forecast ($m), 2007-13 127
Table 46: Gonal-F: overview 128
Table 47: Gonal-F: sales forecast ($m), 2007-13 129
Table 48: Glucophage & Glucovance: overview 132
Table 49: Glucophage & Glucovance: sales forecast ($m), 2007-13 133
Table 50: Merck KGaA's R&D pipeline (Phase I-registration) 134
Table 51: Exchange rates, 2007 137
List of Figures
Figure 1: Merck KGaA prescription pharmaceutical performance, sales ($m) and growth rate (%), 2001-13 5
Figure 2: Merck KGaA's financial performance ($m), 2001-13 6
Figure 3: Merck KGaA's externalization, growth drivers ($m), 2001-13 9
Figure 4: Merck KGaA's biologics focus (percentage of branded ethical sales), 2001, 2006 and 2007 10
Figure 5: Merck KGaA's therapeutic focus (percentage of branded ethical sales), 2001, 2006 and 2007 11
Figure 6: Merck KGaA's geographic focus (percentage of branded ethical sales), 2001, 2006 and 2007 12
Figure 7: Merck KGaA's age of products (percentage of branded ethical sales), 2001, 2006 and 2007 13
Figure 8: Merck KGaA's restructuring and its effects on operating margins, 2001-08e 15
Figure 9: Merck KGaA SWOT analysis 17
Figure 10: Current corporate structure 42
Figure 11: Merck KGaA, business unit focus (% total sales), 2001-07 43
Figure 12: Merck KGaA, pharmaceuticals business units sales ($m), 2001-08e 45
Figure 13: Merck KGaA prescription pharmaceutical performance, sales ($m) and growth rate (%), 2001-13 48
Figure 14: Merck KGaA key sales growth driver & resistors ($m), 2001-07 51
Figure 15: Merck KGaA key sales growth drivers & resistors ($m), 2007-13 54
Figure 16: Merck KGaA prescription pharmaceutical sales by therapy area ($m), 2001-13 56
Figure 17: Merck KGaA prescription pharma sales by therapy area (% of total), 2001-13 61
Figure 18: Merck KGaA prescription pharmaceutical sales by geographic region ($m), 2001-13 63
Figure 19: Merck KGaA growth drivers and resistors by geographic region ($m), 2001-07 64
Figure 20: Merck KGaA drivers and resistors by geographic region ($m), 2007-13 66
Figure 21: Merck KGaA prescription pharmaceutical sales by geographic region (% of total), 2001-13 68
Figure 22: Merck KGaA launch/core/expiry configuration ($m), 2007-13 73
Figure 23: Merck KGaA prescription pharmaceutical sales by molecule type ($m), 2001-13 75
Figure 24: Merck KGaA growth drivers and resistors by molecule type ($m), 2007-13 78
Figure 25: Merck KGaA prescription pharmaceutical sales by source ($m), 2001-13 79
Figure 26: Merck KGaA growth drivers and resistors by source ($m), 2001-07 80
Figure 27: Merck KGaA growth drivers and resistors by source ($m), 2007-13 82
Figure 28: Merck KGaA operating revenue/cost analysis ($m), 2001-13 90
Figure 29: Merck KGaA operating cost ratio analysis (% of total revenues), 2001-13 94
Figure 30: Merck KGaA return on capital employed, EBIT margin and capital turnover, 2001-07 97
Figure 31: Return on capital employed formula 101
Figure 32: Merck KGaA market capitalization ($ billion), 2001-07 104
Figure 33: Merck KGaA total shareholder returns vs. S&P 500 ($m), 2001-07 105
Figure 34: Multiple sclerosis market position of the leading four disease-modifying therapies across the seven major markets, 2007 110
To order this report:
Pharmaceutical Industry: Merck KGaA: PharmaVitae Profile
Check our Company Profile, SWOT and Revenue Analysis!
SOURCE Reportlinker
Back to top
RELATED LINKS
http://www.reportlinker.com
Custom Packages
Browse our custom packages or build your own to meet your unique communications needs.
PR Newswire Membership
Fill out a PR Newswire membership form or contact us at (888) 776-0942.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.
Featured Video
More in These Categories
Journalists and Bloggers
![]()
Visit PR Newswire for Journalists for releases, photos, ProfNet experts, and customized feeds just for Media.
View and download archived video content distributed by MultiVu on The Digital Center.
Free Investing Newsletter from Investor Uprising!
Learn to navigate the world's financial system and profit from leading companies.
Register for Investor Uprising, the people's investment site, for a free weekly newsletter, information, education and premium research including our latest IU Confidential Report - "All That Glitters: The Ultimate Gold Report".
